Name
RF5-05: RADIOLA phase II trial primary analysis: Predicting olaparib sensitivity in patients with HER2- MBC BRCA1/2, PALB2, RAD51C/D mutations by the RAD51 test: Commentary by: William Gradishar, MD, FASCO, FACP
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL